Revance Logo
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
ABOUTLEADERSHIPBOARDPARTNERSHIPS
SUSTAINABILITYMEDICAL EDUCATIONAL GRANTSINVESTIGATOR SPONSORED TRIALS
Company
INVESTOR RELATIONSPRESS RELEASESEVENTS + PRESENTATIONSFINANCIALS & FILINGSCORPORATE GOVERNANCE
STOCK INFORMATIONANALYST COVERAGEINVESTOR FAQSCONTACT US
Investors
OPPORTUNITIESCULTUREBENEFITS
Careers
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
Facebook logoInstagram logoTwitter logoLinkedIn logo
1222 Demonbreun St
20th Floor
Nashville, TN 37203
+1 (510) 742-3400
LoginContact Revance
Back
August 3, 2017
Revance Releases Second Quarter 2017 Results
August 2, 2017
Revance Therapeutics Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics
July 24, 2017
Revance Therapeutics to Release Second Quarter 2017 Financial Results Thursday, August 3, 2017
June 15, 2017
Positive BELMONT Phase 2 Trial Results Published in Dermatologic Surgery
June 5, 2017
Revance Reports Additional Positive Week 24 Efficacy Results from RT002 Injectable Phase 2 Cervical Dystonia Trial
June 1, 2017
Revance to Participate in Upcoming Investor Conferences
May 18, 2017
Revance Announces Positive Top-Line 24-Week Duration of Effect Results in All Three Cohorts in RT002 Injectable Phase 2 Cervical Dystonia Trial
May 9, 2017
Revance Releases First Quarter 2017 Results
May 1, 2017
Revance Provides Update on Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis
April 25, 2017
Revance Therapeutics to Release First Quarter 2017 Financial Results Tuesday, May 9, 2017
Displaying 201 - 210 of 305